THE FEATURES OF THE COURSE OF HBV INFECTION DURING ANTIVIRAL THERAPY
- Authors: OMAROVA K.G.1, MAKASHOVA V.V.1, PONEZHEVA Z.B.1
-
Affiliations:
- Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being
- Issue: Vol 12, No 1 (2022)
- Pages: 60-63
- Section: Articles
- URL: https://journals.eco-vector.com/2226-6976/article/view/287869
- DOI: https://doi.org/10.18565/epidem.2022.12.1.60-3
- ID: 287869
Cite item
Open Access
Access granted
Abstract
Objective. To determine the features of the course of chronic hepatitis B in patients receiving and not receiving antiviral therapy (AVT). Subjects and methods. Seventy HBsAg-positive patients were followed up who had a disease duration from 1 to 15 years; of them there were 24 (34.3%) patients who received AVT with nucleoside analogues (NAs) and 46 (65.7%) who did not receive treatment. Results. During the first visit, the duration of HBsAg release was less than 5 years in 57% of the patients. The number of patients with a duration of HBsAg release for more than 20 years coincided with that of patients (11 %) with severe fibrosis (F3-F4), which was evidenced by fibroelastometry using a FibroScan. HBeAg-negative HBV infection was identified in 86% of the patients; and the initial stage of fibrosis was detected in 83%. AVT was initiated, regardless of the stage of fibrosis, more often in patients aged 41-60 years (in 41.7% of cases) with a viral load of 5 logs. Conclusion. Less than half of the patients who started taking NAs remained adherent to therapy. At the same time, the stage of liver fibrosis decreased in patients receiving AVT, which may suggest that NAs have an anti-fibrotic effect.
Keywords
Full Text
About the authors
Khadizhat G. OMAROVA
Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being
Email: omarova71@inbox;ru
Cand. Med. Sci., Researcher, Clinical Department of Infectious Diseases Moscow, Russia
Vera V. MAKASHOVA
Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being
Email: veramakashova@yandex.ru
Professor, MD, Leading Researcher Moscow, Russia
Zhanna B. PONEZHEVA
Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being
Email: doktoiim@mail.ru
MD, Head, Clinical Department of Infectious Diseases Moscow, Russia
References
- WHO. Global Hepatitis Report 2017. Geneva, Switzerland. World Health Organization, 2017. https://apps.who.rnt/iris/bitstream/handle/10665/255016/9789241565455-eng.pdf
- Fattovich G., Bertoletti F., Donato F. Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors. J. Hepatol. 2008; 48, 335-52. doi: 10.1016/j.jhep.2007.11.011
- MacLachlan J.H.,Cowie B.C. Hepatitis B virus epidemiology. Cold Spring Harb. Perspect. Med. 2015; 5(5): a021410. doi: 10.1101/ cshperspect. a021410
- Ющук Н.Д., Климова Е.А., Знойко О.О., Кареткина Г.Н., Максимов С.Л., Маев И.В. Вирусные гепатиты. Клиника, диагностика, лечение. 2-е изд., перераб. и доп. М.: ГЭОТАР-Медиа, 2015. 302 с.
- Абдурахманов Д.Т. Хронический гепатит В и D. М.: ГЭОТАР-Медиа, 2010. 286 с.
- Weinbaum C., Williams I., Mast E., Wang S.A., Finelli L., Wasley A. et al. Recommendations for identication and public health manage-ment of persons with chronic hepatitis B virus infection. MMWR Recomm. Rep. 2008; 57: 1-20.
- European Association for the Study ofthe Liver. EASL Clinical Practice Guidelines on the management of chronic hepatitis В virus infection. J. Hepatol. 2017; 67(2): 370-98. doi: 10.1016/j.jhep.2017.03.021
- Chou R., Dana T., Bougatsos S., Blazina I., Khangura J., Zakher B. Screening for hepatitis B virus infection in adolescents and adults: a systematic review to update the U.S. Preventive Services Task Force recommendation. Ann.Intern. Med. 2014; 161: 31-45. doi: 10.7326/ M13-2837
- Hoofnagle J.H., Doo E., Liang T.J., Fleischer R., Lok A.S.F. Management of hepatitis B: Summary of a clinical research workshop. Hepatology 2007; 45(4): 1056-75. doi: 10.1002/hep.21627
- Sweetman S., ed. Martindale: the complete drug reference (online version), 37th edition, 2011. http://www.pharmpress.com/product/ MC_MART/ martindale-the-complete-drug-reference
- Terrault N.A., Lok A.S., McMahon B.J., Chang K.-M., Hwang J/P., Jonas M.M. et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 2018; 67(4): 1560-99. doi: 10.1002/hep.29800
- Schiff E.R., Lee S.S., Chao Y.C., You-Chen Chao, Seung Kew Yoon et al. Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin. Gastroenterol. Hepatol. 2011; 9(3): 274-6. DOI: 10.1016/j. cgh.2010.11.040
- Yeo Y.H., Ho H.J., Yang H.I., Tseng T.C., Hosaka T., Trinh H.N. et al. Factors Associated With Rates of HBsAg Seroclearance in Adults With Chronic HBV Infection: A Systematic Review and Meta-analysis. Gastroenterology 2019; 156(3): 635-646.e9. doi: 10.1053/j.gastro.2018. 10.027
- Chu C.M., Liaw Y.F. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology 2007; 45(5): 1187-92. doi: 10.1002/hep.21612
- Okada M., Enomoto M., Kawada N.,Nguyen M.N. Effects of antiviral therapy in patients with chronic hepatitis B and cirrhosis. Expert Rev. Gastroenterol. Hepatol. 2017; 11: 1095-104. doi: 10.1080/17474124. 2017. 1361822
- Marcellin P., Gane E., Buti M., Afdhal N., Sievert W., Jacobson I.M. et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013; 381(9865): 468-75. DOI: 10.1016/ S0140-6736(12)61425-1
- EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. European Association for the Study of the Liver. J Hepatol 2017; 67 (2): 370-398. doi: 10.1016/j.jhep.2017.03.021
Supplementary files
